Shira Zelber-Sagi1,2, Shahar Azar3, Alina Nemirovski3, Muriel Webb1,4, Zamir Halpern1,4, Oren Shibolet1,4, Joseph Tam3. 1. Department of Gastroenterology, Liver Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. 2. School of Public Health, University of Haifa, Haifa, Israel. 3. Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. 4. The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Abstract
OBJECTIVE: To evaluate the association between circulating levels of endocannabinoids (eCBs) and non-alcoholic fatty liver disease (NAFLD). METHODS: The serum levels of the main eCBs, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their endogenous precursor and breakdown product, arachidonic acid (AA), were analyzed by liquid chromatography/tandem mass spectrometry in 105 volunteers screened for NAFLD. Hepatic ultrasound, fasting blood tests, and anthropometrics were assessed. Liver fat was quantified by the hepato-renal-ultrasound index representing the ratio between the brightness level of the liver and the kidney. RESULTS: Patients with NAFLD had higher levels (pmol/mL) of AA (2,721 ± 1,112 vs. 2,248 ± 977, P = 0.022) and 2-AG (46.5 ± 25.8 vs. 33.5 ± 13.6, P = 0.003), but not AEA. The trend for higher levels of AA and 2-AG in the presence of NAFLD was observed in both genders and within subgroups of overweight and obesity. The association of AA and 2-AG with NAFLD was maintained with adjustment for age, gender, and BMI (OR = 1.001, 1.000-1.001 95% CI, P = 0.008 and OR = 1.05, 1.01-1.09, P = 0.006, respectively) or waist circumference. CONCLUSIONS: This study is the first to show high circulating levels of 2-AG and AA in NAFLD patients compared with controls, independent of obesity. The findings may suggest an independent role of eCBs in the pathogenesis of NAFLD.
OBJECTIVE: To evaluate the association between circulating levels of endocannabinoids (eCBs) and non-alcoholic fatty liver disease (NAFLD). METHODS: The serum levels of the main eCBs, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their endogenous precursor and breakdown product, arachidonic acid (AA), were analyzed by liquid chromatography/tandem mass spectrometry in 105 volunteers screened for NAFLD. Hepatic ultrasound, fasting blood tests, and anthropometrics were assessed. Liver fat was quantified by the hepato-renal-ultrasound index representing the ratio between the brightness level of the liver and the kidney. RESULTS:Patients with NAFLD had higher levels (pmol/mL) of AA (2,721 ± 1,112 vs. 2,248 ± 977, P = 0.022) and 2-AG (46.5 ± 25.8 vs. 33.5 ± 13.6, P = 0.003), but not AEA. The trend for higher levels of AA and 2-AG in the presence of NAFLD was observed in both genders and within subgroups of overweight and obesity. The association of AA and 2-AG with NAFLD was maintained with adjustment for age, gender, and BMI (OR = 1.001, 1.000-1.001 95% CI, P = 0.008 and OR = 1.05, 1.01-1.09, P = 0.006, respectively) or waist circumference. CONCLUSIONS: This study is the first to show high circulating levels of 2-AG and AA in NAFLD patients compared with controls, independent of obesity. The findings may suggest an independent role of eCBs in the pathogenesis of NAFLD.
Authors: Hamid Moradi; Christina Park; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Amy S You; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli Journal: Am J Nephrol Date: 2020-01-14 Impact factor: 3.754
Authors: W Taylor Kimberly; John F O'Sullivan; Anjali K Nath; Michelle Keyes; Xu Shi; Martin G Larson; Qiong Yang; Michelle T Long; Ramachandran Vasan; Randall T Peterson; Thomas J Wang; Kathleen E Corey; Robert E Gerszten Journal: JCI Insight Date: 2017-05-04
Authors: Hu Huang; Seung-Hwan Lee; Inês Sousa-Lima; Sang Soo Kim; Won Min Hwang; Yossi Dagon; Won-Mo Yang; Sungman Cho; Min-Cheol Kang; Ji A Seo; Munehiko Shibata; Hyunsoo Cho; Getachew Debas Belew; Jinhyuk Bhin; Bhavna N Desai; Min Jeong Ryu; Minho Shong; Peixin Li; Hua Meng; Byung-Hong Chung; Daehee Hwang; Min Seon Kim; Kyong Soo Park; Maria Paula Macedo; Morris White; John Jones; Young-Bum Kim Journal: J Clin Invest Date: 2018-10-29 Impact factor: 14.808